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Previous experiments (KELLY et al. 1958a, b; M~QvIS  e ta l . ;  
SMITiK et al.) have studied effects of meprobamate  and other psycho- 
active drugs on the objectively measured behavior of normal subjects 
after acute and after chronic administrat ion of the drug treatments.  
The present experiment investigates chronic drug effects on a sample 
of patients psychiatrically diagnosed as anxiety neurotics. This, then, 
allows for extension of our previous findings to a new group of potential  
drug users - -  the more disturbed outpatient,  of psychiatrist  or general 
practitioner, who is likely to be treated for protracted periods under 
close medical supervision. 
The driving, vision, and at tention tests developed and used pre- 
viously were again employed in this experiment, along with new tests 
tha t  appeared promising as anxiety-sensitive indicators. In  addition 
to data from the objective behavioral tests, two other types of data  
were collected - -  psychiatric assessments on a number  of variables, 
and check-list ratings both by  the patients and by  a close friend. 
Method 
Subjects. Thirty-eight  paid volunteers, ranging in age from 21 to 
41 years, were chosen as subjects for the present s tudy of whom thirty- 
two, including 15 men and 17 women, completed the experiment. This 
total  included 23 patients who were diagnosed as anxiety  neurotics on 
the basis of a psychiatric interview and work-up, plus nine normal 
controls. Patients  were recruited from three sources : a) A general practi- 
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tioner in private practice referred a series of his patients, whom he 
diagnosed as anxious, and whom he would normally have t reated with 
psychoactive drugs, b) One hundred and twenty  subjects who vol- 
unteered in response to a newspaper advertisement were pre-screened 
with the Taylor Manifest Anxiety Scale (TAYI~Ol~). This was the source 
for the normal control subjects, e) The Student Heal th  Service of The 
University of Michigan referred studentswho, in the opinion of the Heal th  
Service psychiatrists, manifested neurotic anxiety. These three sources 
were merely the screening channels of entry into the study; all final 
diagnoses were made by the psychiatrist  directly involved, so tha t  
criteria for diagnosis were constant for all patients. 
Two of the six who did not complete the experiment were in the 
anxious group. One of these patients was dropped because of the inten- 
sity of his pathology. (This had been diagnosed prior to the study, and 
clearly was in no way connected with the drug treatments.)  The other 
patient,  along with the three normal subjects, dropped out for financial 
reasons - -  either because he no longer needed the money, or because he 
was forced to move out of town to take a job. The fourth normal 
dropped out because of psychological effects tha t  may  have been related 
to drug t rea tment  (Tranquil). 
Dosages and Treatments. After the pat ient  had been interviewed 
by the psychiatrist  and chosen for the study, the following regime was 
insti tuted: a first behavioral test  session was run under the effects of a 
single oral dose of 15 rag. of phenobarbital,  given one-half hour before 
testing began. No a t t empt  was made to balance the ordering of this 
barbi turate  test  with the rest  of the study. I t  was deemed more de- 
sirable to use this testing session as pre-training on those tasks for which 
practice and familiarization might  play a part,  and to make the actual 
comparison between phenobarbital  and other drug t reatments  only on 
those tests clearly without practice effects. 
Three 21-day periods of pill administration now began, one for each 
treatment.  The ordering of the t reatments  was balanced out across the 
entire group (and within the normal and neurotic sub-groups). Pills 
were put  in unlabelled bottles by a technician not connected with the 
experiment, so tha t  neither experimenter nor pat ient  knew what  treat- 
ment  was being given. However, one innovation, introduced to elimi- 
nate some of the problems of placebo effects, made possible an unforeseen 
type of unblinding of the experimenters. Rather  than administer the 
three different t reatments  in the same pill form, which might have maxi- 
mized placebo effects for the first t rea tment  and almost eliminated them 
for the next  two treatments,  the pills were presented in three different 
forms, matched for size but  with the differences between these forms 
152 
maximized. These forms, however, were identical for a single drug, so 
tha t  if the experimenter were told by the patient  something tha t  identi- 
fied the shape of the pill, he was thus informed of the drug treatment.  
This happened in seven of the 96 testing sessions. Because of the objective 
nature of the behavioral tests, which are not influenced by experi- 
menter  bias, this should have had no effect on the behavioral test phase 
of the study. But  the psychiatric assessment phase of the s tudy was 
subject to the same partial unblinding (in six of 87 interviews), and in 
this ease we can be less certain of the effects. 
Daily dosages were as follows : a) 1600 rag. of meprobamate,  b) five 
Tranquil tablets (the max imum recommended daily dose), and e) five 
large placebo tablets. Tranquil is a combination of a large number of 
drugs, but  its effective components are chiefly bromides. Five tablets 
contain the following amounts:  sodium bromide 0.485 gms., potassium 
bromide 0.97 gms., ammonium bromide 0.164 gins. This drug was tested 
because it had been placed on the market  as an over-the-counter drug 
whose name connoted tranquilizing effects. Thus we compared a tran- 
quilizer with a bromide compound in addition to determining the effects 
of each in relation to a placebo. 
At the end of each of the three t rea tment  periods, patients were seen 
at  two separate sessions: a) for testing on the driving battery,  ortho- 
rater and other behavioral tests, and b) for a psychiatric interview 
(during which 10 ce. of blood was taken, for analysis of bromide level). 
All behavioral testing was done by the same technician; all interviews 
were conducted by the same psychiatrist.  The third phase of the study 
was conducted as follows: Every  seven days the pat ient  mailed in a 
self-report rating schedule, thus giving three weekly cheeks on the 
action of each drug treatment.  In  addition, all patients had a spouse, 
close friend, or roommate (chosen by the patient) mail in similar rating 
forms. These ratings thus allowed for analyses  of subjectively felt 
changes, for changes observed by someone in close daily contact with 
the patient, and for discrepancies between inner feelings and behavior 
observable by another. 
Objective Behavioral Test Battery. The objectively measured vari- 
ables were scored from various aspects of the pat ient 's  performance on 
nine different behavioral tests. Twenty-seven variables were scored 
directly, and three variables were derived as difference or ratio scores 
from these basic variables. These tests, together with the scores ob- 
tained on each, are described below. 
A. Driver Test (7 scores). The American Automobile Association's 
"Auto Trainer" was used. The patient  operated the trainer by working 
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the controls of a conventional shift automobile. A treadmill-like belt 
about 10 feet long, painted to resemble a winding road, extends in 
front of the control unit. A model car, connected to the steering wheel 
and operated by the subject, rests on the belt. The patient 's job is to 
keep the ear on the read and to brake the car whenever a red light 
appears. (For a more complete description of this apparatus, see MAx- 
qVlS et al. 1957). 
Patients were given trials as follows: 20 revolutions of the belt at a 
fixed low speed; 20 at a fixed high speed; and 20 at a speed controlled 
by the subject. Six reaction-time determinations were interspersed 
irregularly through the first two trials. 
Accuracy, or proficiency, of driving in this situation is measured in 
terms of the patient's ability to keep the car on the road. Three accu- 
racy scores were obtained: at the fixed low speed, at the fixed high 
speed, and at the variable patient-controlled speed. A "speed" score 
was also obtained, the time required for the trial when the patient, was 
controlling his own speed. A derived judgment score was also com- 
puted - -  the ratio of the difference between the accuracy score at low 
fixed speed and the accuracy score at patient-controlled speed, divided 
by the time score. 
B. Vision Tests (7 scores). Tests of the various components of vision 
that  might be affected by psychoactive drugs were conducted on the 
Bausch and Lomb master model ortho-rater, an instrument designed to 
control illumination, distance and presentation of visual stimuli (K~LLY 
et al. 1958a; MARQVlS et al.). Acuity was determined for both far and 
near vision; depth perception was determined for distant vision only. 
Vertical and lateral phorias for both. near and far vision were also 
measured. (For a more complete description, see KELL'~ et al. 1958a.) 
C. Kinesthetic Figural A/ter-EJ/ect (1 score). This apparatus, origi- 
nally developed by KSgLE~ and WALLACH (K6HLER and WALLACe), was 
used in an at tempt to follow up evidence that kinesthetic figural after- 
effects are indications of personality disorders. EYsE~cJ~ has found 
that hysterics, as compared with dysthymies (anxious patients), more 
quickly developed IigurM after-effects which were stronger and more 
persistent. KLEI~ and KREC~I found much the same effects for brain 
injured patients, as compared with normal subjects (KLEI~ and K~Ec~ 
1952). 
The patient is blindfolded for this test, so that  he never sees the 
apparatus. Itis task is to judge the width of a 11/2 '' block of wood felt 
between the thumb and forefinger of his left hand. The judgment is 
made both before and after an after-effect is induced. (For a more com- 
plete description, see KELLY et al. 1958a.) Three scores are obtained: 
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1. mean original judgment, 2. mean after judgment, and 3. mean after- 
effect, change (difference in judgment from 1 to 2). Only the second and 
third scores, which measure the after-effect, were analyzed. 
D. Judgment o/Lines Test (2 scores). This test, which forms a part 
of CATT]~LL'S Objective-Analytic Test battery (CATTELL ]955), is said to 
be an objective measure of general anxiety. The patient is instructed 
~o mark an X to show which of two paired lines is the longer, or to 
indicate that  both are of equal length. This is a timed test, in which 
30 seconds are allowed for each of four pages of lines to be compared, 
each page containing 20 pairs of lines. Two scores are obtained : 1. num- 
ber completed, and 2. per cent accuracy. 
E. Tempos and Time Estimations (6 scores). First, the patient 's fast- 
walking rate is determined. Then the patient is asked to set a metro- 
nome at the rate he prefers (KELLY et al. 1958a). Time estimations, 
shown to be drug-sensitive by STnI~B~G (1955) and KLEEMEIR (1956), 
were then taken. The patient was asked to estimate a lapse of 20 seconds 
of time: first, without attempting to count seconds, while a metronome 
beat at the rate of 100 per minute; second, while counting to himself 
(UHR and MILLER, in press). Finally, the patient was asked to set the 
metronome as closely as possible to correspond to two rates - -  first, 
50 beats per minute, and second, 180 beats per minute (UHR and 
MILLER, in press). 
.F. Attention Span (2 scores). Digit span forward and digit span 
backward were both tested and scored. These are simple measures of 
attention span and short-term memory that  have been shown by 
KORNETSKu I~UMPHIClES, and EVAt~TS to be sensitive to psychoactive 
drugs. This test was administered according to standard Wechsler- 
Bellevue procedures (WEcHSLER 1944). 
G. Muscular Persistence (3 scores). Strength and persistence were 
tested using a hand dynamometer. The patient was asked to squeeze 
the dynamometer as hard as he could three times. The dynamometer 
needle was then set at 60% of his third squeeze, and the patient was 
asked to hold the dynamometer needle steady at this point for as long 
as he was able. This test has been said to be sensitive to anxiety (HAMILTO?r 
1955). A second score was analyzed - -  the strength of pull on the first 
trial - -  for a gross check on muscle strength. A third score was de- 
rived - -  the difference between strength of pull on the first trial and the 
second trial - -  as a test of level of aspiration-related motivation. 
H. Hyperventilation Test (2 scores). In this test, the patient is first 
asked to hold his breath as long as he can. He is next told to breathe 
deeply for 30 seconds. He is then to hold his breath as long as he can. 
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This test has been shown by MllCSKY et al. (1946) and by FRIEDMAN 
(1947) to discriminate between normals and neurotics. Two scores were 
analyzed: the difference in length of time breath was held before and 
after hyperventilation, and the absolute length of time breath was held 
after hyperventilation. 
Psychiatric Interview. Fifteen aspects of the patient 's reactions to 
the drug treatments were objectified and tested for the significance of 
drug effects. The psychiatrist who interviewed patients at the end of each 
drug period developed his own quantification methods and converted 
his interview notes and work-up into 3-point ratings on each of the 
scales he devised. These included three general types of scales: a) rel- 
atively objective self-observations reported by the patient : skin changes, 
physical changes, daytime sleepiness, night sleep, and appetite; b) rel- 
atively subjective self-observations reported by the patient : reactions to 
the treatment,  restfulness, changes in physical effort required, activity 
of the drug, and liking for the drug; and e) ratings of the patient by 
the psychiatrist: concentration, retention, motivation, tension, improve- 
ment. This is a rough trichotomy; it  should be remembered that  all 
three types of source material for these ratings were filtered through 
the psychiatrist, who synthesized and made a clinical judgment of his 
interview material, and then quantified these judgments on 3-rating 
scales of the different behaviors observed. Complete data for this phase 
of the study were collected for 29 people. 
Blood Bromide Level. A sixteenth measure was made from blood 
collected at the time of the psychiatric interview - -  the determination 
of blood bromide level, in milligrams per 100 cubic centimeters of blood. 
Complete data for this part  of the study were collected for 26 people. 
Weekly Ratings by Self and by Other. All patients filled out and 
returned a self-report schedule every seven days, or three  times during 
each of the three t reatment  periods. In addition, the spouse, room- 
mate, or intimate friend separately filled out and returned two schedules, 
one characterizing himself, the other characterizing the patient in the 
experiment. 
Fifteen variables, representing only a portion of these data, have 
been scored and analyzed at this time. Because of the magnitude of 
the analysis task, only the third report on each drug, which should give 
the cumulative effect of the drug treatment,  was used. The first and 
second reports would allow for further analysis of the weekly time 
response effects of the treatment.  
Semantic Differential self-reports, as modified and used in previous 
drug studies (KELLY et al. 1958a), were scored for the three factors 
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identified by OSGOOD (1957): 1. evaluative, 2. activity, and 3. potency. 
An adjective check list was derived from two sources. First, a check 
list designed by NOWLIS (NowLIs and GREEN 1957) was shortened by 
taking the five adjectives with the highest loadings on each of the eight 
factors identified by him. An additional scale was constructed from 
adjectives that  subjects in the study of chronic drug effects conducted 
by KELLY et al. (1958a) had most frequently used to characterize their 
subjective changes. 
Only four of the nine scales - -  those that  appeared to be most 
closely related to drug effects - -  were scored and analyzed. These 
scales were 1. Concentration, 2. Activation vs. Deactivation, 3. Anxiety, 
and 4. Subject-Reported Drug Effects. These four scales were each 
scored for the following : a) the patient's rating of himself, b) the other's 
rating of the patient, and c) the discrepancy between the patient's and 
the other's rating of the patient. 
Results 
0bjeetive Behavioral Tests. Table 1 presents the mean performances 
on each of the objectively scored behavioral tests under each of the 
continued drug treatments, for the total group of 32. (The effects of 
the acute administration of phenobarbital will be reported elsewhere.) 
The difference between the mean performance (Table 1) under one 
treatment as compared to another, when evaluated in terms of the 
standard error (an estimate of the amount these means might differ as 
a result of chance alone), gives the magnitude of the difference in effect 
Table 1. Mean performance under meprobamate, Tranquil, and placebo on ob#ctive 
behavioral tests 
Tes t  
Accuracy (higher score better) 
Low speed . . . . . . . . . . . .  
High speed . . . . . . . . . . .  
Variable speed . . . . . . . . . .  
Time: 
Variable speed (higher score better) . 
Reaction time (lower score better): 
Low speed . . . . . . . . . . . .  
High speed . . . . . . . . . . .  









Mean pe r fo rmance  under  
mepro-  















Tes t  
Table  1 (con t inued  
Vari- Mean performance under 
able mepro- 
No. bamate  Tranquil  placebo 
B. Vision (h igher  score bet ter )  
Acuity: 
Near  . . . . . . . . . . . . . .  8. 9.97 
F a r  . . . . . . . . . . . . . . .  9. 8.90 
P horia : 
Ver t i ca l -nea r  . . . . . . . . . .  10. 4.7 
Ver t ica l - fa r  . . . . . . . . . . .  11. 5.1 
L a t e r a l - n e a r  . . . . . . . . . . .  12. 7.1 
La te ra l - f a r  . . . . . . . . . . . .  13. 8.1 
Depth: . . . . . . . . . . . . . .  14. 4.0 
C. Kinesthetic a/ter.e/#ct (h igher  score be t te r )  
I 15. I 2.321 
D. Line ]u@ment (h igher  score be t te r )  
Oom io od . . . . . . . . . . . .  I 
Pe r  cen t  correct  . . . . . . . . . .  17. 76.2 
E. Tempos and times 
Pre/erred tempo (h igher  score be t t e r ) :  
F a s t  . . . . . . . . . . . . . . .  
Sub jec t  se t  . . . . . . . . . . .  
Time estimation (h igher  score be t t e r ) :  
N o t  coun t i ng  . . . . . . . . . . .  








50/rain. (lower score bet ter )  . . . . .  
180/min.  (h igher  score be t te r )  . . . .  
F. Digit span (h igher  score be t te r )  
F o r w a r d  . . . . . . . . . . . . .  , 24. , 7.2 
B a c k w a r d  . . . . . . . . . . . .  [ ] 25. 5.5 
G. Muscular persistence (h igher  score b e t t e r  
T i m e  he ld  a t  60% . . . . . . . . .  I 26. 40.5 
S t r e n g t h  of pul l  . . . . . . . . .  ] 27. 41.2 
I m p r o v e m e n t  of pul l  . . . . . . .  28. 
H. Hyperventilation (h igher  score be t t e r  
Dif ference  a f te r  . . . . . . . . . .  I 29. I 17.5 



























40.4 - - 1 8  41.0 
12.7 17.9 
52.3 59.3 
b e t w e e n  t h e  t w o  t r e a t m e n t s ,  a n d  t h e  p r o b a b i l i t y  t h a t  t h i s  d i f f e r e n c e  i s  
a d e p e n d a b l e  o n e ,  a n d  n o t  t h e  r e s u l t  o f  m e r e  c h a n c e .  T a b l e  2 p r e s e n t s  
158 
T a b l e  2. Magnitude and signi/icance o/ di//erences in per/ormance on the ob#etive 
behavioral tests,/or the di//erent contrasts in treatments 
[P l u s  v a l u e  (no  s ign)  i n d i c a t e s  t h a t  p e r f o r m a n c e  w a s  b e t t e r  u n d e r  f i r s t  t r e a t -  
m e n t . ]  
Signi f icance  of d i f ference 
Vari- (C/R.) in per formance  under  
Tes t  able 
No. meproba~nate  T r a n q u i l  
Accuracy: 
L o w  s p e e d  . . . . . . .  
H i g h  s p e e d  
V a r i a b l e  s p e e d  
Time: 
V a r i a b l e  s p e e d  
Reaction time: 
L o w  s p e e d  
H i g h  s p e e d  
Judgment: . . . . . . . .  
Acuity: 
N e a r  . . . . . . . . . .  
F a r ,  
P horia : 
V e r t i c a l - n e a r  
V e r t i c a l - f a r  
L a t e r a l - n e a r  
L a t e r a l - f a r  
Depth: . . . . . . . . . .  
C o m p l e t e d  
2. 
3. 
vs. p l acebo  
A. Driving 
- - 0 . 6 1  
- -  1.26 
- -  1 . 9 9  
- -  2 .56  
- - 1 . 3 1  







- -  1 . 7 8  
- -  1.88 
- -  2 . 9 2 " *  
- 3 .25 
- -  0.84 
B. Vision 
- -  1 . 8 2  
- -  1 . 3 7  
- -  1.05 
- - 1 . 1 2  
10. 0 .77 
1.82 
11. - - 0 . 7 1  
0 .00  
12. 1.58 
2 .00  
13. - -  0 .82 
- -  0 .59  
- -  0 .45  
- -  0.87 
C. Kinesthetic a]ter-e]]ect 
I 15. I o . so  
D. Line judgment 
0.14 
m e p r o b a m a t e  
vs. p lacebo  vs. T r a n q u i l  
0.53 - -  1.02 
- - 0 . 7 1  - - 0 . 6 2  
- -  1.35 - -  0 .60  
- -  1.76 - -  0 .70  
- -  1.10 0.01 
- -  1.06 0 .70  
- -  1 . 3 3  1.53 
- -  1.61 2.13 
- -  1.06 - -  0 .73 
- -  0 .40  - -  1.78 
- - 2 . 4 4 *  - - 0 . 1 4  
- -  2 .23  0.57 
- -  1.85 1.22 
- -  1.96 * 0 .24  
- - 1 . 1 7  - - 0 . 1 1  
- -  1 .20 1.38 
- -  1 .20 0 .70  
0 .00  0.63 
0.67 0.63 
- -  1.33 0.91 
- -  1.33 1.43 
- -  1.33 2 .33  * 
- -  1.16 2 .50  
- -  0 .95  - -  0.57 
0 .00  - -  0 .67 
- -  0 .42 0 .00  
- -  0 .43 - -  0 .32  
0 .09  0.82 
- -  1.17 0 .55  
- -  0 .96 1.25 
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Test 
Per  cent correct 
Table 2 (continued) 
Significance of difference 
Vari- (C. R.) in performance under 
able 
No. meprobamate Tranquil 
vs. placebo vs. placebo 
I 17. 1.13 0.34 
0.75 0.28 





- -  0.96 
--0 .61 






- -  0.40 
0.50 
- -  0.35 
- -  0.33 
Pre/erred tempo: 
F a s t  . . . . . . . . . .  
Subject  set  . . . . . . .  
Time estimation: 
Not  count ing . . . . . .  
Count ing . . . . . . . .  
Rate estimation: 
50/rain . . . . . . . . . .  
180/min . . . . . . . . .  
22. 
23. 
F. Digit span 
Forward  . . . . . . . .  I_....~__. I _. 0.48 24. 00
Backward  . . . . . . .  - -  1.18 
-- 0.45 
G. Muscular persistence 
Time held at  60% . . . .  ] 26. ] 0.05 
I [ 
0.79 
S t reng th  of pull . . . . .  ~ - -  0.19 
0.20 
I m p r o v e m e n t  of pull . . . 28. 1.40 
H. Hyperventilation 
Difference af ter  . . . . .  29. [ - -0 .19  





--  1.09 O.O3 
- -  2.38 1.20 
- -  0.28 - -  0.31 





- -  0.59 0.35 
0.23 0.94 
- -  0.54 0.35 
- -  0.15 --  0.30 
--  1.18 0.77 
- -  0.43 0.00 
- -  0.53 - -  0.56 
0.00 - -  0.48 
- -  1 . 0 3  1 . 4 8  
- -  0.10 1.16 
- -  0.52 0.69 
- -  0.37 0.54 
1.91 --  0.98 
- -  1 . 6 5  1 . 5 7  
- -  2.27 * 2.83 ** 
- -  2.59 2.92 
1. The first  line for each variable presents  the  Critical Rat io  for the  tota l  
group (N ~ 32). The second line for the  anxious subgroup  (N = 23). 
2. D a t a  on derived scores were no t  analyzed for the  anxious  subgroup.  
Significant C. l~.'s are s ta r red  only for the  tota l  g roup  (the top  lines). 
* Significant beyond  the  5 % level of probabil i ty.  
** Significant beyond  the  1% level of probabi l i ty .  
Psychopharmacologia, Bd. 1 11 
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the results of this evaluation -- the magnitudes of the critical ratios for 
the comparisons between treatments: I. meprobamate vs. placebo, 
2. Tranquil vs. placebo, 3. meprobamate vs. Tranquil. A plus value 
(no sign) indicates that performance was better under the first as con- 
trasted with the second treatment in the comparison. The first line for 
each variable gives the Critical Ratio for the total sample (N~32), 
the second line for the subsample of 23 anxious patients. 
Table 3. Mean psychiatric ratings o/ patients under meprobamate, Tranquil, and 
placebo 
(The scale name characterizes the high end of the scale.) 
Rating dimension 
1. Marked reaction . . . . . . . . . .  
2. Marked daytime sleepiness . . . . 
3. Longer nighttime sleep . . . . . .  
4. More restfulness . . . . . . . . .  
5. Better concentration . . . . . . . .  
6. Better retention . . . . . . . . .  
7. Better motivation . . . . . .  ' . .  
8. Less physical effort required . . . .  
9. Less tension . . . . . . . . . .  
10. Increased appetite . . . . . . . .  
11. Marked skin change . . . . . . .  
12. Severe physical change . . . . .  ; 
13. Drug was active . . . . . . . . .  
14. Subject feels better . . . . . . .  
15. Subject likes drug . . . . . . . .  
M e a n  rating u n d e r  
I 
m e p r o -  i T r a n -  p l a -  
b a m a t e  I q u i l  c e b o  
- - I  
2.4 2.3 1.8 
1.9 1.8 1.3 
2.4 2.4 1.8 
2.4 2 .2  2.0 
1.9 1.6 1.8 
2.0 1.7 1.8 
1.7 1.6 1.8 
1.8 1.8 2.0 
2.4 2.1 ].9 
1.7 1.7 2.0 
0.0 0.2 0.0 
0.1 0.3 0.0 
2.1 2.0 1.6 
2.5 2.3 2.3 
2.1 1.7 2.1 
Psych i a t r i c  E v a l u a t i o n .  T a b l e  3 p resen t s ,  for  t h e  t o t M  g r o u p  (29) 
for  w h o m  c o m p l e t e  d a t a  f r o m  t h e  p s y c h i a t r i c  e v a l u a t i o n s  are  ava i l ab le ,  
t h e  m e a n  score  on each  of t h e  15 a spec t s  of b e h a v i o r  q u a n t i f i e d  a n d  
r a t e d  b y  t h e  i n t e r v i e w i n g  p s y c h i a t r i s t .  
T a b l e  4 p r e s e n t s  t h e  s ign i f i cance  of t h e  d i f fe rences  b e t w e e n  t h e  
r a t i n g s  in  T a b l e  3 a f t e r  each  d r u g  t r e a t m e n t  as c o m p a r e d  w i t h  each  
o t h e r  t r e a t m e n t .  A p lus  v a l u e  (no sign) i n d i c a t e s  a m o r e  des i rab le  
r a t i n g  o n  t h a t  scale for  t h e  f i r s t  as c o n t r a s t e d  w i t h  t h e  second  t r e a t m e n t  
in  t h e  c o m p a r i s o n .  
Blood  B r o m i d e  Levels .  T a b l e  5 p r e s e n t s  t h e  m e a n  b l o o d  b r o m i d e  
l eve l  u n d e r  each  of t h e  t h r ee  t r e a t m e n t s ,  a n d  t h e  s ign i f icance  of t h e  
d i f fe rences  in  t he se  leve ls  b e t w e e n  t h e  t h r e e  c o m b i n a t i o n s  of t r e a t m e n t  
N = 2 6 ) .  
T r a n q u i l  t r e a t m e n t  led  t o  a h i g h l y  s i gn i f i c an t  r ise  in  b lood  b r o m i d e  
evel ,  a n d  t o  occas iona l  sk in  r eac t ions .  
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Self a n d  O t h e r  R a t i n g  Schedu le s .  T a b l e  6 p r e s e n t s  t h e  m e a n  scores  
o n  a) t h e  s e v e n  v a r i a b l e s  s c o r e d  f r o m  s e l f - r e p o r t  m a t e r i a l s  ( a f t e r  t h r e e  
w e e k s  of t h e  d r u g ) ,  b)  t h e  f o u r  v a r i a b l e s  s c o r e d  f r o m  r a t i n g s  of t h e  
p a t i e n t  m a d e  b y  a n o t h e r  p e r s o n ,  a n d  c) t h e  f o u r  d i f f e r e n c e  scores  d e r i v e d  
Table 4. Magnitude and signi/icance o/ di//erences in psychiatric evaluations /or 
the di/]erent contrasts in treatment 
[Plus value (no sign) indicates bet ter  rat ing under  first t rea tment . ]  
Rating dimension 
1. Marked reaction . . . . . . .  
2. Marked dayt ime sleepiness . . . 
3. Longer night t ime sleep . . . .  
4. More restfulness . . . . . . .  
Significance of difference (C. R.) under 

















--  0.50 
4.29 ** 
3.13 
- -  1 . 5 4  
0.00 
m 
- - ~ 1 . 4 3  1 . 5 4  
5. Bet ter  concentrat ion . . . . .  0.91 - -1 .54 2.00* 
6. Bet ter  re tent ion . . . . . . .  2.00" --  0.91 3.00 ** 
0.77 
-- 2.86 * 8. Less physical effort required . . - -2 .86** 0.00 
0.00 - -  1 . 8 2  11. Marked skin change . . . . . .  
9. Less tension . . . . . . . . .  3.13 ** 1.33 1.67 
10. Increased appet i te  . . . . . .  - -  2.31 * --  2.14 * 0.00 
2.50 * 
12. Severe physical change . . . .  1.43 1.36 0.87 
13, Drug was active . . . . . . .  2.63** 2.11" 0.67 
1 . 6 7  - -  - -  
14. Subject  feels be t t e r  . . . . . .  0.91 0.00 1.00 
15. Subject  likes drug . . . . . . .  0.00 --  1.90 1.38 ~ 
1. C. i%.'s for the  neurotic subgroup are reported only when they are discrepant 
from the  C.R. 's  for the  to ta l  group. 
2. Significant C.R. 's  are s tarred only for the to ta l  group. 
* Significant beyond the  5 % level of probabili ty.  
** Significant beyond the 1% level of probabili ty.  
t o  i n d i c a t e  t h e  m a g n i t u d e  oil  d i s c r e p a n c i e s  b e t w e e n  s u b j e c t i v e l y  f e l t  
r e a c t i o n s  a n d  the ,  d e g r e e  t o  w h i c h  t h e s e  r e a c t i o n s  a re  o b s e r v a b l e  b y  
a n o t h e r  p e r s o n .  
T a b l e  7 :p resen t s  t h e  s i g n i f i c a n c e  of t h e  d i f f e r e n c e s  b e t w e e n  t h e  
scores  i n  T a b l e  6 a ~ t e r  e a c h  t h r e e - w e e k  d r u g  t r e a t m e n t  as  c o m p a r e d  
w i t h  e a c h  o t h e r  t r e a t m e n t .  A p lu s  v a l u e  (no  s i g n )  i n d i c a t e s  a m o r e  
d e s i r a b l e  r a t i n g  o n  t h e  f i r s t  as  c o n t r a s t e d  w i t h  t h e  s e c q n d  t r e a t m e n t .  
11" 
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Tab le  5. Analysis of blood bvomide levels 
A. Milligrams o/bromide ]ound per hundred cubic centimeters of blood after treatment 
I Mean bromide level under 
meprobamate Tranquil  placebo 
I 
Bromide  (mg. pe r  cent)  . . . . . .  ] 3.98 40.76* 4.24 
* Bromide  levels  u n d e r  T r a n q u i l  r a n g e d  to  a h igh  of 61 rag. per  cent .  
B. Magnitude and significance of differences in blood bromide level/or the di/]erent 
contrasts in treatment 
Significance of difference under 
meprobamate  Tranquil  Tranquil  vs. 
vs. placebo vs. placebo meprobamate 
Bromide  . . . . . . . . . . . .  - - 0 . 1 8  15 .73"*  13.16 ** 
** S ign i f ican t  b e y o n d  t he  1% level  of p robabi l i ty .  
Tab le  6. Mean check list ratings for patients under meprobamate, Tranquil, and placebo 
t Mean rating under 

















Ratings of patient by himself 
Semantic differential (lower score 
ind ica tes  more)  : 
P o t e n t  . . . . . . . . . . . .  4.51 
H i g h  e v a l u a t i o n  . . . . . . . .  3.05 
Ac t ive  . . . . . . . . . . . .  3.42 
Ratings of patient by himself 
Ad#ctive check list (h igher  score I 
ind ica tes  more)  : 
I A. Concen t r a t i on  . . . . . . . .  6.5 B.  A c t i v a t i o n  vs.  d e a c t i v a t i o n  . . 19.1 C. A n x i e t y  . . . . . . . . . .  19.8 D. Sub jec t - r epo r t ed  s y m p t o m s .  . 17.1 
Ratings of patient by other observer 
Ad#ctive check list (h igher  score 
ind ica tes  more)  : 
A. C o n c e n t r a t i o n  . . . . . . . .  6.8 
B.  D e a c t i v a t i o n  vs .  a c t i va t i on  . . 18.8 
C. A n x i e t y  . . . . . . . . . .  18.1 
D.  Sub jec t - r epo r t ed  s y m p t o m s . .  16.2 
Discrepancy between self and 
Adjective check list: 
A. C o n c e n t r a t i o n  . . . . . . . .  0.3 
B.  A c t i v a t i o n  vs.  deac t i va t i on  . . 0.3 
C. A n x i e t y  . . . . . . . . . .  1.7 














- - 0 . 3  
- - 1 . 5  
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Table 7. Magnitude and significance of differences in cheek list scores for the different 
contrasts in treatment 
Check list  dimension 
Signiiicance of difierence (C. R) under 
mcprobamatc  [ Tranqui l  meprobamate  
vs. placebo I vs. placebo 
Ratings of patient by himself 
Semantic differential: [ 
Potent  . . . . . . . . . . . .  0.91 
High evaluation . . . . . . . .  0,37 
Active . . . . . . . . . . . .  ] 0.92 
Ratings o/patient by himsel] 
Adjective check list: 
A. Concentration . . . . . . . .  - -  0.60 
B. Activation vs. deativaction . . --0.14 
C. Anxiety . . . . . . . . . .  1.59 
D. Subject-reported symptoms 1.24 
Ratings o[ patient by other observer 
Adjective check list: 
A. Concentration . . . . . . . .  
B. Activation vs. deactivation . . 
C. Anxiety . . . . . . . . . .  
D. Subject-reported symptoms.  . 
- -  0.06 
--  0.07 
- -  1 . 0 2  





- -  0 . 1 9  - -  1.60 
- -  --  2.08 
--  1.96 * --  0.93 
--  2.55 
2.74"* 3.04 ** 





--  0.55 
1.36 
0.17 
--  0.60 
1.49 
- -  1 . 6 2  
0.28 
Discrepancy between self and other ratings 
Adjective check list: 
A. Concentration . . . . . . . .  0.00 --  0.25 0.34 
B. Activation vs. deactivation . . 0.00 0.78 --0.77 
C. Anxiety . . . . . . . . . .  2.58 ** 1.33 1.30 
D. Subject-reported symptoms.  . 1.20 0.54 0.79 
1.C.R.'s for the neurotic subgroup ~re reported only when they are discrepant 
from C.g . ' s  for the total group. 
* significant beyond the 5 % level of probability. 
** Significant beyond the 1% level of probability. 
D i s c u s s i o n  
B e h a v i o r a l  Tests .  T h e  d i s c r e p a n c i e s  in  r e s u l t s  b e t w e e n  t h e  p r e s e n t  
a n d  p r e v i o u s  s t u d i e s  (MARQVIS e t  al. ; K ~ L Z u  c t  al. 1958a) of t h e  be-  
h a v i o r a l  e f f ec t s  of m e p r o b a m a t e  i n d i c a t e  t h a t  t h e s e  r e s u l t s  s h o u l d  be 
e v a l u a t e d  w i t h  e x t r e m e  cau t i on .  F o r  t h e  f i r s t  t i m e  in  t h e  ser ies  of 
e x p e r i m e n t a l  s t u d i e s  of m e p r o b a m a t e  w i t h  w h i c h  t h e  a u t h o r s  h a v e  
b e e n  a s s o c i a t e d ,  s o m e  p s y c h o m o t o r  e f fec t s  a p p e a r  to  h a v e  b e e n  d e t e c t e d  
on  t h e  c o m p l e x  d r i v e r  t a sk .  I n  t h i s  s t u d y  m e p r o b a m a t e  p r o d u c e d  a 
s l igh t ,  b u t  s i gn i f i c an t ,  s l owing  of r e a c t i o n  t i m e  (of t h e  o r d e r  of a 4 %  de-  
c r e m e n t ) ,  c o u p l e d  w i t h  a s l i gh t  d e c r e a s e  in  a c c u r a c y  a t  f a s t  speed .  Of 
t h r e e  e x p e r i m e n t s  e m p l o y i n g  t h e  d r i v i n g  t e s t ,  t h i s  r e s u l t  h a s  a p p e a r e d  
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only in  the experiment tha t  tested the effects of meprobamate on 
anxious patients. 
Other experiments on meprobamate's effects on driving skills (M~- 
LA~D~ 1957) and on psychomotor performance (I~ITAN 1957 ; Ko~- 
N]STSKu 1958) have confirmed our previous findings of little or no 
effects, with the single exception of a study by Loo~Is and WnsT (1958), 
in which eight subjects showed shght (10%) but  statistically significant 
decrements in an index of driving proficiency after a single (400 rag.) 
dose of meprobamate. One possibility that  presents itself is that,  be- 
cause LooMIs and W~sT tested an extremely small group of subjects 
in their experiment, a sample biased toward neuroticism might have 
been unwittingly employed, and characterized as "normal".  
The actual mechanism of meprobamate's action on behavior may 
be clarified by the increase in accuracy of time estimation found in the 
present study when a distracting and misleading influence (a metro- 
nome beating at 100 per minute) was introduced. Possibly mepro- 
bamate aids the patient in concentrating, in cutting out and selecting 
from sensory inputs. This finding is further confirmed by a pilot study 
reported by CLA~K, in which subjects were asked to perform a task 
that  would occupy them - -  to copy random letters - -  and at the same 
time to at tend and respond to a barely audible buzzer. Increase in 
concentration and the resulting narrowing of attention would lead to 
poorer performance on this task, and significantly poorer performance 
was in fact observed under the influence of meprobamate, as con- 
trasted with placebo. Meprobamate's benign effect on phoria might be 
another indication of this phenomenon. In this test, unless the patient 
throws himself completely into the task, it  is possible for eye convergence 
to be incomplete. Finally, the decrement in driving performance could 
result from a change in concentration. On the driving test the patient 
must first track the car; but  second, he must occasionally respond to 
an extraneous stimulus - -  the red light. Here again, the subsidiary 
response, the reaction time, is primarily affected. 
As contrasted with meprobamate, Tranquil appears to have a similar, 
but  slightly lessened, effect on driving - -  leading to a significant slowing 
of reaction time, accompanied by a slighter, and nonsignificant, decrease 
in accuracy at high speed. Lateral phoria (near) and time estimations 
under distraction are significantly poorer under Tranquil than under 
meprobamate. Within the  anxious subgroup, Tranquil has the effect 
of increasing the speed at  which the patient chooses to drive when he 
is given control of the accelerator of the car, a possible indication of 
tendencies toward-over-confidence or recklessness. Significant shorten- 
ing of the length of time breath can be he ld  indicates a possibility of 
undesirable effects. Decreased visual acuity (near) and the preference 
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for a slower "hurrying" rate under Tranquil would also seem to be 
possible impairing factors. 
Psychiatric Assessment. Marked effects, for both drugs, were found 
in the analysis of the variables quantified from the psychiatric assess- 
ments. This phase of the study should be examined with caution, 
however, because of the inherent difficulties in conducting a blind study 
when the measuring instrument (in this case, the examining psychia- 
trist) is not objective, tIower, this would appear to have been as 
little subject to unblinding as any study of this sort. Quantification 
was not begun until the entire study was completed, so that the 
psychiatrist worked only with his interview notes; and tipoffs of drug 
treatments may have been forgotten by this time. 
On the whole, the psychiatrist's picture of meprobamate's effect 
seems clear. Patients appear more rested, less tense, more active, and 
have better retention. Yet they do not subjectively "feel better", nor 
do they "like" the drug. No change in their motivation level can be 
noted. They feel sleepy and sleep more, but this is true predominantly 
of the normal as opposed to the anxious patients. Appetite is lowered, 
and the patients feel that more physical effort is required of them to 
conduct their day-to-day activities. 
Tranquil shared with meprobamate the significant general reaction, 
greater physical effort required, decreased appetite, and feeling of 
greater drug activity. Again, no change in motivation level was felt, 
nor any subjective sensation of "feehng better", nor any special "liking" 
for the drug. Tranquil led to greater sleepiness and longer nighttime 
sleep; but, whereas for meprobamate this affected primarily the normal 
subjects, those who would usually not take the drug, for Tranquil this 
affected primarily the group of anxiety neurotics. Further, whereas 
meprobamate gave a feeling of greater restfulness, Tranquil did not. 
Tranquil, in contrast, led to poorer retention and poorer concentration 
than meprobamate. 
Finally, Tranquil led to significant physiological effects of the sort 
that would be expected from a bromide compound. Significantly more 
skin and miscellaneous physical changes (dry mouth, bad taste, and, in 
subjects with seborrhoeie skins, an exacerbation of the acneic condition) 
occurred under Tranquil, and the blood bromide level was much higher. 
Cheek List Reports. None of the self-reports indicated any statisti- 
cally significant effects. The factor scores from reports by roommates, 
good friends, or spouses gave significantly lower activity ratings to the 
anxious group when under Tranquil, but significantly lower anxiety 
ratings to the total group when under meprobamate. When patients 
were characterized for components of behavior that are related to drug 
effects, both Tranquil and meprobamate led to significantly better 
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characterizations. LASKu et al. (1959) have shown that  fellow patients 
in a psychiatric ward appear to be at least as good observers of behavior 
of one another as the professional workers (nurses, attendants, psychia- 
trists, psychologists). These results would again appear to confirm the 
power of this type of non-professional third person observation. 
There appears to be a possibility that  the meprobamate effect may 
be specific to the anxious, neurotic patient and the result not of direct 
impairment of psychomotor skills, but rather of increased ability to 
concentrate and concomitant lessened ability to shift attention. If this 
suggestion is tenable, it does not appear to hold for Tranquil, for which 
our tests give no picture of improved concentration. The most plausible 
interpretation of these results, then, might be that  different mechanisms 
underlie the behavioral changes produced by these two drugs - -  that  
meprobamate decreases anxiety level and increases ability to concen- 
trate, while Tranquil lowers self-watchfulness and judgment and impairs 
concentration. Resultant behavior and symptomatic changes, though 
differently caused, appear in certain aspects similar. 
Summary 
The effects of chronic administration of (a) 1600 mg. mcprobamate, 
(b) five Tranquil tablets (the maximum recommended daily dose), and 
(c) placebos were examined, in a counterbalanced partially blinded 
design. Thirty-two subjects, including 23 anxious patients, employed 
as their own controls, were given behavioral tests, psychiatric inter- 
views, and ratings at the end of each 21 day treatment period. 
On the behavioral tests, meprobamate led to a slowing of reaction 
time in simulated driving at high speed, accompanied by a slight lower- 
ing of accuracy, and an improvement in accuracy of time estimations 
under a distracting influence. Tranquil led to a similar slowing of reac- 
tion time at high speed, along with a nonsignificant tendency toward 
decreased accuracy, and significantly poorer visual acuity and hyper- 
ventilation scores. 
On psychiatric evaluations, meprobamate led to marked psycho- 
logical reactions, daytime sleepiness, longer nighttime sleep, greater 
restfulness, better retention, need for more physical effort, less tension, 
decreased appetite, and a feeling that  the drug was active. Tranquil led 
to similar effects as to psychological reactions, daytime sleepiness, night- 
time sleep, need for more physical effort, decreased appetite, and judg- 
ment of drug activity but no increase in restfulness, improved retention, 
or lessened tension. 
Self-ratings did not differentiate between the three treatments. 
Ratings by observers indicated decreased anxiety under meprobamatc 
and decreased symptoms under both treatments. 
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